Protein Disulfide Isomerase Family A Member 4 (PDIA4), also known as ERP72, is an essential endoplasmic reticulum (ER) resident chaperone that catalyzes protein folding, disulfide bond formation, and isomerization. Emerging research highlights PDIA4 as a critical driver of chemoresistance, tumor cell survival under hypoxia, islet beta-cell dysfunction in diabetes, and platelet activation. Consequently, targeting PDIA4 with selective small-molecule inhibitors or therapeutic antibodies represents a highly promising therapeutic strategy in oncology, metabolic diseases, and thrombosis.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PDIA4 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PDIA4 Recombinant Protein (Human, Mouse, Cyno) High purity (>95%), Endotoxin Controlled. Sequence Verified. Available in His-tag or GST-tag for assay flexibility. |
View PDIA4 Products |
| Gene Delivery | PDIA4 Promise-ORF / Lentivirus Full-length ORF lentiviral particles for stable cell line construction and overexpression validation. |
View PDIA4 Products |
| Benchmark Ab | Anti-PDIA4 Recombinant Antibody High-affinity positive control for ELISA, Western Blot, and functional blocking assays. |
View PDIA4 Products |
| Validator | PDIA4 siRNA Set Target-specific siRNA pool for target knockdown and specificity validation in cell-based assays. |
View PDIA4 Products |
| Related Target A | P4HB (PDIA1) Primary PDI family member. Essential for counter-screening to ensure drug selectivity and avoid off-target toxicity. |
View P4HB Products |
| Related Target B | PDIA3 (ERp57) Closely related isomerase involved in MHC class I peptide loading. Crucial for selectivity profiling. |
View PDIA3 Products |
| Related Target C | PDIA6 ER stress-associated isomerase. Important for comprehensive family-wide selectivity panels. |
View PDIA6 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Family-wide Off-target Cross-reactivity | Recombinant active catalytic domains of PDIA1, PDIA3, PDIA4, and PDIA6 available with >95% purity for high-throughput selectivity screening. |
| Assay Interference from Endotoxin | Endotoxin levels strictly controlled (<1.0 EU/μg) to prevent non-specific immune activation in cell-based assays. |
| Lack of Validated Control Reagents | Sequence-verified clinical-grade benchmark recombinant antibodies and validated siRNA knockdowns included. |
| Conformational Integrity in Cell Assays | Lentiviral vectors optimized for stable, native-conformation overexpression in target cell lines. |
Live PDIA4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of PDIA4 is transitioning from academic validation to industrial drug development. While traditional protein disulfide isomerase (PDI) inhibitors faced challenges due to poor selectivity across the PDI gene family, modern drug discovery focuses on achieving high selectivity for PDIA4. In oncology, PDIA4 upregulation is directly correlated with resistance to chemotherapy (e.g., cisplatin, paclitaxel) and targeted therapies. Inhibiting PDIA4 restores apoptotic pathways in cancer cells under ER stress. In metabolic diseases, selective PDIA4 inhibition protects pancreatic beta-cells from ER-stress-induced apoptosis, presenting a novel disease-modifying mechanism for Type 2 Diabetes.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Institutes, Biotech Startups | Colorectal Cancer, Glioblastoma, Type 2 Diabetes | Selectivity Assay (Need highly purified PDIA4 vs PDIA1/PDIA3/PDIA6 mutant & WT proteins) |
| Monoclonal Antibodies | Biopharma Innovators | Surface-expressed PDIA4 in Platelet Disorders, Advanced Solid Tumors | Epitope mapping and binding affinity (Need native-conformation HEK293-expressed PDIA4) |
| RNA Therapeutics (siRNA/ASO) | RNAi Specialists | Hepatic/Metabolic Diseases, Chemoresistant Tumors | In vitro target knockdown validation (Need high-specificity siRNA and quantitative qPCR/WB controls) |